SOLICITATION NOTICE
A -- Bangkok Tenofovir Drug Study
- Notice Date
- 11/14/2008
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- CDC52306
- Response Due
- 11/29/2008
- Archive Date
- 12/14/2008
- Point of Contact
- Patrick W Gourley,, Phone: 770-488-2825
- E-Mail Address
-
pgourley@cdc.gov
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC) intends to award a modification to an existing contract with the Bangkok Tenofovir Study Group on a noncompetitive, cost only (no fee) basis. The Bangkok Tenofovir Study (BTS) is a Phase II/III randomized, double-blind, placebo-controlled study of the safety and efficacy of tenofovir, administered once daily to HIV-1 uninfected Intravenous Drug Users in Bangkok Thailand. The study is designed to determine if daily tenofovir will prevent HIV-1 infection among IDUs and if tenofovir is safe to use among HIV-uninfected IDUs. The purpose of this contract is to continue the study initiated under an existing contract with the Bangkok Tenofovir Study Group (contract 200-2007-21481) to allow an extension of enrollment and participant follow up. BTS is designed to determine if daily tenofovir will prevent HIV-1 infection among IDUs and if tenofovir is safe to use among HIV-uninfected IDUs. This is a Phase II/III randomized, double-blind placebo controlled study of the safety and efficacy of tenofovir, administered once daily to HIV-1 uninfected IDUs. HIV-uninfected IDUs will be randomized to receive either tenofovir 300 mg daily or placebo. Participants will be involved in the study until the last enrollee completes 12 months on study, with an expected extended contract period from January 2009 through September 2010. For continuation and consistency of this research it is imperative to utilize BTSG for this follow-on contract. BTSG's ability to continue their work will prevent this trial from ending prematurely or will prevent CDC from having to start this research project from the beginning. The North American Industry Classification Code is 541712.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=63c2809f81a62e4025bd25383e78ff10&tab=core&_cview=1)
- Place of Performance
- Address: Bangkok, Thailand
- Record
- SN01705411-W 20081116/081114220752-63c2809f81a62e4025bd25383e78ff10 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |